Bendamustine Hydrochloride

09/01/2018 - "High-dose Bendamustine-EAM followed by autologous stem cell rescue results in long-term remission rates in lymphoma patients, without renal toxicity."
02/15/2015 - "We conclude that the high efficacy of bendamustine in treating CLL might be partly contributed to the expression of OAT3 in lymphoma cells and the high affinity of bendamustine for this transporter. "
08/01/2002 - "Bendamustine as a single agent is effective against aggressive lymphoma, even in cases of refractory disease. "
06/01/2019 - "In this study, we aimed to determine the safety and efficacy of bendamustine in the conditioning regimen for autologous SCT in refractory/relapsed lymphomas. "
01/01/2021 - "Effectiveness of bendamustine in relapsed or refractory lymphoma cases: a Turkish Oncology Group study."

08/01/2002 - "Bendamustine is effective in relapsed or refractory aggressive non-Hodgkin's lymphoma."
09/01/2018 - "For non-Hodgkin lymphoma, mobilization with bendamustine is safe and effective."
11/14/2022 - "[Bendamustine monotherapy for Chinese patient treatment with relapsed or refractory B cell non-Hodgkin lymphoma: a phase Ⅱ, prospective, multicenter, single-arm study]."
05/06/2021 - "Bendamustine treatment of Chinese patients with relapsed indolent non-Hodgkin lymphoma: a multicenter, open-label, single-arm, phase 3 study."
12/01/2015 - "Prior studies found bendamustine is efficacious in patients with indolent B-cell non-Hodgkin lymphoma (NHL). "

11/01/2013 - "Bendamustine proved to be effective for the treatment of chronic lymphocytic leukemia (CLL). "
11/01/2009 - "Bendamustine: a new treatment option for chronic lymphocytic leukemia."
10/01/2005 - "Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I/II study of the German CLL Study Group."
01/01/2001 - "In an open phase-II study we treated 23 patients with a median age of 62 years at study entry (43-86 years) with advanced, refractory or relapsed (Rai stage III n = 9, Rai stage IV n = 14) chronic lymphocytic leukemia (CLL) with bendamustine. "
05/01/2017 - "A multicenter, single-arm, Phase II clinical trial of bendamustine monotherapy in patients with chronic lymphocytic leukemia in Japan."

12/01/2015 - "This multicentre phase II trial evaluated the pharmacokinetics (PK), safety and efficacy of bendamustine monotherapy in Chinese patients in Taiwan with pretreated indolent B-cell NHL or mantle cell lymphoma (MCL). "
01/01/2022 - "Survival in mantle cell lymphoma after frontline treatment with R-bendamustine, R-CHOP and the Nordic MCL2 regimen - a real world study on patients diagnosed in Sweden 2007-2017."
10/22/2019 - "Five-year outcomes of the S1106 study of R-hyper-CVAD vs R-bendamustine in transplant-eligible patients with mantle cell lymphoma."
07/01/2015 - "This study was a postapproval commitment to investigate bendamustine's effect on cardiac repolarization in treatment-naïve adults with advanced indolent NHL/mantle cell lymphoma (MCL). "
09/01/2010 - "In this multicenter phase II trial, the efficacy and safety of bendamustine were evaluated in Japanese patients with relapsed or refractory indolent B-NHL or mantle-cell lymphoma (MCL). "

01/01/2017 - "R-Bendamustine is an effective treatment for follicular lymphoma (FL). "
01/01/2021 - "The patient had a past medical history of grade III follicular lymphoma for which he completed six cycles of bendamustine 4 years before presentation and had been in remission since. "
10/01/2023 - "Impact of immunochemotherapy with R-bendamustine or R-CHOP for treatment naïve advanced-stage follicular lymphoma: A subset analysis of the FOLL12 trial by Fondazione Italiana Linfomi."
03/01/2022 - "Reduced bendamustine for elderly patients with follicular lymphoma."
11/01/2009 - "A 64-year-old white female had recently received treatment with bendamustine for stage III follicular lymphoma. "